Pmsc-11: pioneering liver failure treatment with stem cells

When you have your aged or damaged organ failing, you need a powerful solution for organ rejuvenation. Immorta Bio’s Stem Cell Revivify™ might be that solution…future solution. Read Hot Science below.

All of us want to live longer and healthier. Investors know that…Read Hot Investments below.

‍

Hot Science

Immorta Bio has filed a patent for a potentially groundbreaking treatment for liver failure: PMSC-11, a novel stem cell therapy. Pre-clinical studies using PMSC-11 on animal models of liver failure yielded promising results. The therapy not only preserved essential liver functions like albumin production, but also prevented the typical rise in liver enzymes associated with liver damage.

However, PMSC-11 goes a step further. It also triggered a significant increase in a specific cytokine, a signaling molecule linked to enhanced recovery from liver failure. This additional benefit suggests PMSC-11 may not just protect the liver, but actively promote its healing. This innovative therapy uses "younger" personalized mesenchymal stem cells, which Dr. Thomas Ichim, Immorta's CSO, believes may offer superior results on the path of solving this unmet need.  

With liver failure ranking as the fifth leading cause of death globally and limited treatment options beyond transplantation, Immorta Bio is actively preparing for clinical trials to bring this potential lifeline to patients.

‍

Hot Investments

Investors are all over the life extension industry and they are supporting not just entrepreneurs’ journeys toward novel therapeutics approval by FDA.  Launched in 2022, Fay, that  connects users with qualified dietitians through an insurance-friendly platform has just received $25 million in funding.

To possibly make it more “palatable” to investors, the Fay cofounder, Mark Stefanski, ties this diet-based path to medicine, when he says: "With the undeniable link between diet and well-being, Fay empowers individuals to use food as medicine."

‍

Longevity Shorts

• Tether invests $200 million in Blackrock Neurotech, entering the neurotechnology field to develop thought-powered solutions for paralysis and neurological disorders.

• Dr. Thomas Ichim, President and CSO of Immorta Bio, will attend the 2024 BIO International Convention in San Diego from June 3-6, and will be conducting one-to-one meetings with potential partners, collaborators, and investors.

• NeuroClues secures €5 million to launch eye-tracking technology for diagnosis of neurological disorders, like Parkinson disease, Alzheimer disease, and multiple sclerosis years before symptoms appear.

‍

Term of the Day

Organ Failure: Organ failure signifies a critical decline in an organ's ability to function, disrupting homeostasis at the cellular level. It's characterized by dysfunctional cells, impaired communication between them, and increased cell death.

‍

Boris Reznik, PhD
Chairman

‍